Go Pro
→ The retirement stock I'd buy before Nvidia today (From Chaikin Analytics) (Ad)tc pixel Free SUN Stock Alerts

Surgical Innovations Group (SUN) Competitors

Surgical Innovations Group logo
GBX 0.45 +0.03 (+5.88%)
As of 11:36 AM Eastern
Compare

SUN vs. AVO, ODX, CNSL, MHC, and BELL

Should you buy Surgical Innovations Group stock or one of its competitors? Surgical Innovations Group's main competitors and comparable companies include Advanced Oncotherapy (AVO), Omega Diagnostics Group (ODX), Cambridge Nutritional Sciences (CNSL), MyHealthChecked (MHC), and Belluscura (BELL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Surgical Innovations Group compare to Advanced Oncotherapy?

Advanced Oncotherapy (LON:AVO) and Surgical Innovations Group (LON:SUN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

In the previous week, Surgical Innovations Group had 1 more articles in the media than Advanced Oncotherapy. MarketBeat recorded 1 mentions for Surgical Innovations Group and 0 mentions for Advanced Oncotherapy. Surgical Innovations Group's average media sentiment score of 0.75 beat Advanced Oncotherapy's score of 0.00 indicating that Surgical Innovations Group is being referred to more favorably in the news media.

Company Overall Sentiment
Advanced Oncotherapy Neutral
Surgical Innovations Group Positive

Advanced Oncotherapy has a net margin of 0.00% compared to Surgical Innovations Group's net margin of -4.96%. Surgical Innovations Group's return on equity of -6.04% beat Advanced Oncotherapy's return on equity.

Company Net Margins Return on Equity Return on Assets
Advanced OncotherapyN/A -67.34% -11.73%
Surgical Innovations Group -4.96%-6.04%-3.03%

17.8% of Advanced Oncotherapy shares are owned by institutional investors. Comparatively, 2.8% of Surgical Innovations Group shares are owned by institutional investors. 47.5% of Advanced Oncotherapy shares are owned by insiders. Comparatively, 22.2% of Surgical Innovations Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Advanced Oncotherapy has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market. Comparatively, Surgical Innovations Group has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

Surgical Innovations Group has higher revenue and earnings than Advanced Oncotherapy. Surgical Innovations Group is trading at a lower price-to-earnings ratio than Advanced Oncotherapy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced OncotherapyN/AN/A-£32.60M-£0.07N/A
Surgical Innovations Group£11.60M0.36N/A-£0.10N/A

Summary

Surgical Innovations Group beats Advanced Oncotherapy on 7 of the 11 factors compared between the two stocks.

How does Surgical Innovations Group compare to Omega Diagnostics Group?

Omega Diagnostics Group (LON:ODX) and Surgical Innovations Group (LON:SUN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Omega Diagnostics Group has a beta of 3.85, indicating that its share price is 285% more volatile than the broader market. Comparatively, Surgical Innovations Group has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

In the previous week, Surgical Innovations Group had 1 more articles in the media than Omega Diagnostics Group. MarketBeat recorded 1 mentions for Surgical Innovations Group and 0 mentions for Omega Diagnostics Group. Surgical Innovations Group's average media sentiment score of 0.75 beat Omega Diagnostics Group's score of 0.00 indicating that Surgical Innovations Group is being referred to more favorably in the news media.

Company Overall Sentiment
Omega Diagnostics Group Neutral
Surgical Innovations Group Positive

Surgical Innovations Group has higher revenue and earnings than Omega Diagnostics Group. Surgical Innovations Group is trading at a lower price-to-earnings ratio than Omega Diagnostics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omega Diagnostics Group£7.55M0.00-£3.17M-£0.01N/A
Surgical Innovations Group£11.60M0.36N/A-£0.10N/A

Surgical Innovations Group has a net margin of -4.96% compared to Omega Diagnostics Group's net margin of -51.15%. Surgical Innovations Group's return on equity of -6.04% beat Omega Diagnostics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Omega Diagnostics Group-51.15% -29.14% -10.53%
Surgical Innovations Group -4.96%-6.04%-3.03%

29.8% of Omega Diagnostics Group shares are held by institutional investors. Comparatively, 2.8% of Surgical Innovations Group shares are held by institutional investors. 50.6% of Omega Diagnostics Group shares are held by company insiders. Comparatively, 22.2% of Surgical Innovations Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Surgical Innovations Group beats Omega Diagnostics Group on 7 of the 11 factors compared between the two stocks.

How does Surgical Innovations Group compare to Cambridge Nutritional Sciences?

Surgical Innovations Group (LON:SUN) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

2.8% of Surgical Innovations Group shares are held by institutional investors. Comparatively, 1.6% of Cambridge Nutritional Sciences shares are held by institutional investors. 22.2% of Surgical Innovations Group shares are held by insiders. Comparatively, 7.8% of Cambridge Nutritional Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cambridge Nutritional Sciences has a net margin of 16.94% compared to Surgical Innovations Group's net margin of -4.96%. Cambridge Nutritional Sciences' return on equity of 12.15% beat Surgical Innovations Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Surgical Innovations Group-4.96% -6.04% -3.03%
Cambridge Nutritional Sciences 16.94%12.15%-2.36%

Surgical Innovations Group has higher revenue and earnings than Cambridge Nutritional Sciences. Surgical Innovations Group is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgical Innovations Group£11.60M0.36N/A-£0.10N/A
Cambridge Nutritional Sciences£8.06M0.53-£3.03M£0.603.01

In the previous week, Surgical Innovations Group had 1 more articles in the media than Cambridge Nutritional Sciences. MarketBeat recorded 1 mentions for Surgical Innovations Group and 0 mentions for Cambridge Nutritional Sciences. Surgical Innovations Group's average media sentiment score of 0.75 beat Cambridge Nutritional Sciences' score of 0.00 indicating that Surgical Innovations Group is being referred to more favorably in the media.

Company Overall Sentiment
Surgical Innovations Group Positive
Cambridge Nutritional Sciences Neutral

Surgical Innovations Group has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Cambridge Nutritional Sciences has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market.

Summary

Cambridge Nutritional Sciences beats Surgical Innovations Group on 7 of the 12 factors compared between the two stocks.

How does Surgical Innovations Group compare to MyHealthChecked?

MyHealthChecked (LON:MHC) and Surgical Innovations Group (LON:SUN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

In the previous week, Surgical Innovations Group had 1 more articles in the media than MyHealthChecked. MarketBeat recorded 1 mentions for Surgical Innovations Group and 0 mentions for MyHealthChecked. Surgical Innovations Group's average media sentiment score of 0.75 beat MyHealthChecked's score of 0.00 indicating that Surgical Innovations Group is being referred to more favorably in the news media.

Company Overall Sentiment
MyHealthChecked Neutral
Surgical Innovations Group Positive

MyHealthChecked has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, Surgical Innovations Group has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

0.7% of MyHealthChecked shares are owned by institutional investors. Comparatively, 2.8% of Surgical Innovations Group shares are owned by institutional investors. 9.3% of MyHealthChecked shares are owned by insiders. Comparatively, 22.2% of Surgical Innovations Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Surgical Innovations Group has a net margin of -4.96% compared to MyHealthChecked's net margin of -49.51%. Surgical Innovations Group's return on equity of -6.04% beat MyHealthChecked's return on equity.

Company Net Margins Return on Equity Return on Assets
MyHealthChecked-49.51% -22.78% -8.18%
Surgical Innovations Group -4.96%-6.04%-3.03%

Surgical Innovations Group has higher revenue and earnings than MyHealthChecked. Surgical Innovations Group is trading at a lower price-to-earnings ratio than MyHealthChecked, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MyHealthChecked£3.22M1.48-£1.04M-£3.76N/A
Surgical Innovations Group£11.60M0.36N/A-£0.10N/A

Summary

Surgical Innovations Group beats MyHealthChecked on 9 of the 12 factors compared between the two stocks.

How does Surgical Innovations Group compare to Belluscura?

Belluscura (LON:BELL) and Surgical Innovations Group (LON:SUN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Belluscura has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Surgical Innovations Group has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

Surgical Innovations Group has a net margin of -4.96% compared to Belluscura's net margin of -2,243.45%. Surgical Innovations Group's return on equity of -6.04% beat Belluscura's return on equity.

Company Net Margins Return on Equity Return on Assets
Belluscura-2,243.45% -97.35% -43.53%
Surgical Innovations Group -4.96%-6.04%-3.03%

In the previous week, Surgical Innovations Group had 1 more articles in the media than Belluscura. MarketBeat recorded 1 mentions for Surgical Innovations Group and 0 mentions for Belluscura. Surgical Innovations Group's average media sentiment score of 0.75 beat Belluscura's score of 0.00 indicating that Surgical Innovations Group is being referred to more favorably in the news media.

Company Overall Sentiment
Belluscura Neutral
Surgical Innovations Group Positive

Surgical Innovations Group has higher revenue and earnings than Belluscura. Surgical Innovations Group is trading at a lower price-to-earnings ratio than Belluscura, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Belluscura£1.80M1.67-£29.55M-£13.10N/A
Surgical Innovations Group£11.60M0.36N/A-£0.10N/A

0.2% of Belluscura shares are held by institutional investors. Comparatively, 2.8% of Surgical Innovations Group shares are held by institutional investors. 7.1% of Belluscura shares are held by insiders. Comparatively, 22.2% of Surgical Innovations Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Surgical Innovations Group beats Belluscura on 9 of the 12 factors compared between the two stocks.

Get Surgical Innovations Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SUN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SUN vs. The Competition

Export
MetricSurgical Innovations GroupHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£4.20M£5.76B£7.20B£2.89B
Dividend Yield2.63%1.75%2.53%6.17%
P/E Ratio-4.5025.87272.63364.82
Price / Sales0.3671.01616.7383,676.90
Price / Cash5.0333.0576.9827.89
Price / Book0.456.0812.856.75
Net IncomeN/A£147.75M£3.47B£5.89B
7 Day PerformanceN/A-1.36%-0.22%-0.78%
1 Month Performance-10.89%5.89%8.04%2.38%
1 Year Performance-32.43%6.67%25.08%22.66%

Surgical Innovations Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SUN
Surgical Innovations Group
N/AGBX 0.45
+5.9%		N/A-39.8%£4.20M£11.60MN/A80
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/AN/A3,900
ODX
Omega Diagnostics Group
N/AN/AN/AN/A£5.23M£7.55MN/A91
CNSL
Cambridge Nutritional Sciences
N/AGBX 2.10
+10.5%		N/A-35.8%£5.00M£8.06M3.503,200
MHC
MyHealthChecked
N/AGBX 9.15
+1.7%		N/A-9.9%£4.76M£3.22MN/A16

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SUN) was last updated on 9/2/2026 by MarketBeat.com Staff.
From Our Partners
This little-known gold fund distributes cash every Friday
Gold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...
Investors Alley | Sponsoredtc pixel
Gold Explorer Sits Between Barrick’s Nevada Giants
Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...
Wall Street Logic | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
#1 Stock to Own as Trump Launches Historic Mission Backing "Medical AI"
The federal government is throwing its full support behind a new class of AI technology, in what's being calle...
Stansberry Research | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Jon Najarian's #1 Energy Trade for 2026
Elon Musk just built the largest private power network in American history. Hall of Fame Trader Jon Najarian s...
Banyan Hill Publishing | Sponsoredtc pixel